Key result
Etiological treatment with benznidazole was successfully completed in a 52-year-old male with dextrocardia and Chagas disease, resulting in stable clinical evolution at one-year follow-up.
Why the study?
Little is known about patients with Chagas disease and anatomical defects such as dextrocardia.
Case Report (n=1)
Etiological treatment for Chagas disease with benznidazole is feasible and acceptable in patients with congenital anatomic abnormalities such as dextrocardia, provided there is close monitoring for adverse effects.
Chagas testing may be considered in endemic patients with dextrocardia and arrhythmias; leaves open prevalence and clinical implications.
Introduction: About half a million patients in Colombia are currently infected with Trypanosoma cruzi. However, little is known about patients with Chagas disease and anatomical defects such as dextrocardia. Case presentation: A 52-year-old male patient with a 4-year history of dyspnea, chest pain, lower limb edema and syncope (requiring hospitalization), arrhythmias and dextrocardia, underwent serological tests for T. cruzi that were positive. A literature review was conducted to find case reports of patients with dextrocardia or situs inversus and Chagas disease in order to determine the proper treatment. Conclusion: Cases of patients with dextrocardia and Chagas disease are rare. Besides the reported case, only three other cases were found in the literature, which were relatively similar, although they could be considered more severe. According to the findings, the use of etiological treatment is acceptable in patients with coronary anatomic abnormalities and T. cruzi infection. The present case draws attention to the importance of adequately approaching and monitoring this type of patient.
No takes yet. Share an insight, caveat, or question.
Porras-Villamil et al. (2021) conducted a case report in Dextrocardia and Chagas disease (n=1). Benznidazole was evaluated on Clinical evolution and treatment success. Etiological treatment with benznidazole was successfully completed in a 52-year-old male with dextrocardia and Chagas disease, resulting in stable clinical evolution at one-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: